Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer
暂无分享,去创建一个
D. Takahari | H. Osumi | K. Yamaguchi | T. Wakatsuki | E. Shinozaki | M. Ogura | K. Shimozaki | A. Ooki | I. Nakayama | D. Kamiimabeppu | Taro Sato | K. Chin